GYKI 52466

GYKI 52466 is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC50 values of 7.5 and 11μM, respectively. GYKI 52466 has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 can be used in Parkinson's disease research[1][2].

Product Specifications

CAS Number

[102771-26-6]

UNSPSC

12352005

Hazard Statement

H315-H319-H335

Target

IGluR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/gyki-52466.html

Solubility

10 mM in DMSO

Smiles

NC1=CC=C(C2=NN=C(C)CC3=CC4=C(OCO4)C=C32)C=C1

Molecular Formula

C17H15N3O2

Molecular Weight

293.32

Precautions

P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P362+P364-P403+P233-P405-P501

References & Citations

[1]S D Donevan, et al. GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron. 1993 Jan;10 (1) :51-9.|[2]A G Chapman, et al. The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466, in mice. Epilepsy Res. 1991 Jul;9 (2) :92-6.